Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study

Hultcrantz, Malin, Björkholm, Magnus, Dickman, Paul W., Landgren, Ola, Derolf, Åsa R., Kristinsson, Sigurdur Y., Andersson, Therese M.L.·2018·Annals of Internal Medicine
DOI 10.7326/m17-0028

Cited by (266)

Items 201–266 of 266

  1. The Value of [ 18 F]FDG PET/CT for Differentiating Neoplastic From Benign Thrombus
    Xiaofeng Dou, Congcong Yu, Chenxi Xue, Jing Wang, Chentao Jin, Yan Zhong, Rui Zhou, Xiaohui Zhang, Hong Zhang · 2025 · iRadiology
  2. Hypoxia-inducible factors contribute to venous thrombosis in a mouse model of myeloproliferative neoplasms
    Shatadal Ghosh, Joanna Mikłosz, Fatima Trebak, Julie Tourn, Steven Philip Grover, Rafał Pawliński, Brandi Reeves · 2025 · Blood Advances
  3. Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study
    Nurgul Batyrbekova, Anna Ravn Landtblom, Malin L. Hultcrantz, Robert Szulkin, Paul William Dickman, Therése Andersson · 2026 · European Journal Of Haematology
  4. Complex Aortic Plaques and Polycythemia Vera Presenting as Blue Toe Syndrome Without Peripheral Arterial Disease
    Sneha Chebrolu, Shannon O'Connor, Sean Doherty, Arjun Aggarwal, M Octavia Rangel · 2026 · JACC Case Reports
  5. [Clinical analysis of head and neck malignant tumor patients with postoperative venous thromboembolism].
    Jian Xiao, Yexun Song, Guolin Tan · 2021 · PubMed Central
  6. Essential Thrombocythemia: One-Center Data in a Changing Disease
    Nicoleta Pîrciulescu, Mihnea‐Alexandru Găman, Marina Mihailescu, Cristina Constantin, Mihaela Dragomir, Camelia Marioara Dobrea, Simona Costache, Iulia Ursuleac, Daniel Coriu, Ana Manuela Crişan · 2022 · Medicina
  7. Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)–negative myeloproliferative neoplasms
    Shirong Wen, Wenxiao Zhang, Yiping Fei, Ke Guan, Hui Zhao, Song Peng, Xiangmei Ye, Yujun Pan · 2024 · Journal of Clinical Neuroscience
  8. Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera
    Jingbo Yu, Julie A Gayle, Ning An Rosenthal, Harold Brown, Evan M. Braunstein, Naveen Pemmaraju · 2025 · The Oncologist
  9. Budd–Chiari Syndrome and Myeloproliferative Neoplasms
    Valerio De Stefano, Elena Rossi · 2019 · Springer eBooks
  10. Atypical Myocardial Infarction with Apical Thrombus and Systemic Embolism: A Rare Presentation of Likely JAK2 V617F-Positive Myeloproliferative Neoplasm
    M. Atere, Rana Al-Zakhari, J. Collins, F. Rotatori, L. Muzangwa · 2020 · Case Reports in Oncological Medicine
  11. Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?
    Francesca Schieppati, Anna Falanga · 2021 · Hematology
  12. Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms
    Maria Teresa Bochicchio, Valeria Di Battista, Pietro Poggio, Giovanna Carrà, Alessandro Morotti, Mara Brancaccio, Alessandro Lucchesi · 2022 · Cancers
  13. Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms
    Jie V. Zhao, Catherine Mary Schooling · 2018 · Annals of Internal Medicine
  14. WITHDRAWN: Women, thrombosis, and cancer
    Dominique Farge, Christine Le Maignan, Ludovic S. Doucet, Corinne Frère · 2019 · Thrombosis Research
  15. Le urgenze ematologiche
    Guest Editors M. Scudeletti, Rodolfo Tassara, G. Antonucci · 2019 · Italian Journal of Medicine
  16. Virchow's Triad in Action
    Adam Karevoll, Trek Langenhan, Allison Ashford · 2020 · Graduate Medical Education Research Journal
  17. Polycythemia Vera: Is It Time to Rethink Treatment?
    Barbara Mora, Francesco Passamonti · 2021 · Clinical Lymphoma Myeloma & Leukemia
  18. Modelling multiple time-scales with flexible parametric survival models
    Nurgul Batyrbekova, Hannah Bower, Paul William Dickman, Anna Ravn Landtblom, Malin L. Hultcrantz, Robert Szulkin, Paul C. Lambert, Therése Andersson · 2022 · Research Square
  19. Ischemia acuta degli arti inferiori: tecniche, indicazioni e complicanze
    Jean‐Baptiste Ricco, R. Belmonte, Thanh-Phong Le · 2022 · EMC - Tecniche Chirurgiche Vascolare
  20. Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy
    Tiziano Barbui · 2022 · Bleeding Thrombosis and Vascular Biology
  21. COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS
    Oksana M. Kostiukevych, L. K. Benkovska, А.М. Kravchenko, T.Ya. Chursina, Кyrylo О. Mikhaliev · 2022 · Clinical and Preventive Medicine
  22. Mechanisms Contributing to Acquired Activated Protein C Resistance in Patients Treated with Thalidomide: A Molecular Dynamics Study
    Correa Lara Maximiliano, Jaime Garcı́a-Chávez, Vega Lopez Armando, Israel Lara-Vega, Victoria Noemi Hernández-González, Erika Martinez Hernandez · 2022 · Cardiovascular & Haematological Disorders - Drug Targets
  23. Data from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms
    Anish V. Sharda, Thomas Bogue, Alexandra Barr, Lourdes Mendez, Robert C. Flaumenhaft, Jeffrey I. Zwicker · 2023
  24. Data from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms
    Anish V. Sharda, Thomas Bogue, Alexandra Barr, Lourdes Mendez, Robert C. Flaumenhaft, Jeffrey I. Zwicker · 2023
  25. Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms
    Alessandro Maria Vannucchi, Paola Guglielmelli · 2023 · JACC CardioOncology
  26. Treatment Algorithm for Polycythemia Vera
    Jeanne M. Palmer, Ruben A. Mesa · 2023 · Springer eBooks
  27. The Role of Leukocytes in the Formation of Neutrophil Extracellular Traps and Thrombosis in Ph-Negative Myeloproliferative Neoplasms: A Literature Review
    Dzhumabaeva Bt · 2023 · Clinical oncohematology
  28. Agent Orange Exposure Enhances the Increased Risk of Cardiovascular Disease in Veterans with Myeloproliferative Neoplasms
    Andrew Chua Tiu, Zoe McKinnell, Puneet Gill, Martha Antonio, Zoe Shancer, Nandan Srinivasa, Shanshan Liu, Guoqing Diao, Ramesh Subrahmanyan, Craig M. Kessler et al. · 2023 · SSRN Electronic Journal
  29. Facilitating clinical trials in Polycythemia vera (PV) by identifying patient cohorts at high near-term risk of thrombosis using rich data and machine learning
    Ghaith F. Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Michael Scandura · 2024 · medRxiv
  30. Central Retinal Vein Occlusion as the Debut of a Chronic Myeloproliferative Neoplasm
    Larisa Konstantinovna Moshetova, L. B. Egoryan, Olga Vinogradova, Д. И. Шихбабаева, Ksenia I. Turkina · 2024 · Ural Medical Journal
  31. The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients
    Soo-Mee Bang, Ji Yun Lee, Ju Hyun Lee, Woochan Park, Jeongmin Seo, Min-Su Kang, Eun Hee Jung, Sang‐A Kim, Koung Jin Suh, Ji‐Won Kim et al. · 2024 · Research Square
  32. Pulmonary Hypertension in Adults with Congenital Heart Disease
    Konstantinos Dimopoulos, Andrew Harry Constantine · 2024 · Springer eBooks
  33. Assessing the risk of venous thromboembolism and bleeding among patients with myeloproliferative neoplasms undergoing total knee and hip arthroplasty
    Josué Marquez, Samantha J. Simon, Jeffrey I. Zwicker, Robert C. Flaumenhaft, Brian L. Hollenbeck, Rushad D Patell · 2024 · Leukemia Research
  34. Polycythemia vera with acute coronary syndrome and bleeding as initial presentation: A case report and literature review
    Rabia Iqbal, Aemen Shafqat Bazaz, Ahmad Taimoor Bajwa, Hnin Nadi Linn, Nyan Linn Htet, Sabrin Akter Marowa, Asmat Ullah · 2024 · Radiology Case Reports
  35. Long-Standing Thrombocytosis and Thrombotic Events Preceding Recognition of Polycythemia Vera: A Single-Center Retrospective Study
    Evgenia LASPA, Francesco Grandoni, Lorenzo Alberio, Grégoire STALDER · 2024 · Research Square
  36. Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system
    Evelyn Walter, Francesca Torelli, Tiziano Barbui · 2025 · Annals of Hematology
  37. Intersecting Pathologies: Polycythemia Vera and Recurrent Infections in an Elderly Patient
    Prince Saha, Emre Sahin, Nirupam Nadella, Adil M Siddiqui, Lokesh R Edara · 2025 · Cureus
  38. Mitigation of atrial fibrillation‐related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG‐MPN bioregistry
    Hyunyee Rosa Cho, Susanne Isfort, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Florian Heinrich Heidel, Martin Grießhammer, Holger Schulz, Andreas Hochhaus, Joachim Rudolf Göthert et al. · 2025 · HemaSphere
  39. Myocardial infarction in a young man with ulcerative colitis and polycythemia vera: а case report
    Е. В. Гордеева, З. Г. Татаринцева, M. V. Alexeenko, K. O. Barbukhatti, E. D. Kosmacheva · 2025 · Russian Journal of Cardiology
  40. Investigation of Two Potential Predictors of Thrombosis Risk in Polycythemia Vera: Hematocrit-to-Hemoglobin Ratio and HALP Score
    Deniz Yılmaz, Eyyüp Akkaya · 2025 · Clinical and Applied Thrombosis/Hemostasis
  41. Влияние терапии на показатели, характеризующие состояние системы свертывания крови у пациентов с эссенциальной тромбоцитемией
    Силина Наталья Николаевна, Olga Golovina, Корсакова Наталья Евгеньевна, Olesya Yu. Matvienko, L. R. Tarkovskaya, Т.В. Морозова · 2025 · Гематология Трансфузиология Восточная Европа
  42. Platelets Fuel Thromboinflammation Through Immunophenotypic and Transcriptomic Alterations in Philadelphia-Negative Myeloproliferative Neoplasms
    Vitor Leonardo Bassan, Poliana Carina Paolini, Lilian Maria Garcia Ramos, Fabiana Rossetto de Morais, Luciana Ambrósio, LFP Chaim, Patrícia Vianna Bonini Palma, Camila Bonaldo, Rafaela de Freitas Martins Felício, Lorena Lobo de Figueiredo‐Pontes et al. · 2025 · SSRN Electronic Journal
  43. Predictive Value of RDW and RCI Indices in Pulmonary Embolism: Insights from Breast Cancer, Lung Cancer, and Non-Cancer Patients
    Özlem Düvenci Birben, Esma Sevil Akkurt, Summeyye Buket Cokelik, Derya Yenibertiz · 2025 · Clinical and Applied Thrombosis/Hemostasis
  44. Additional file 3 of Modelling multiple time-scales with flexible parametric survival models
    Nurgul Batyrbekova, Hannah Bower, Paul William Dickman, Anna Ravn Landtblom, Malin L. Hultcrantz, Robert Szulkin, Paul C. Lambert, Therése Andersson · 2022 · Figshare
  45. Additional file 2 of Modelling multiple time-scales with flexible parametric survival models
    Nurgul Batyrbekova, Hannah Bower, Paul William Dickman, Anna Ravn Landtblom, Malin L. Hultcrantz, Robert Szulkin, Paul C. Lambert, Therése Andersson · 2022 · Figshare
  46. Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm
    Miku Hirose, Yoshihisa Nakano, Shiro Adachi, Tomomi Sugiyama, Masahiro Yoshida, Toyoaki Murohara · 2025 · Circulation Reports
  47. Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the ‘unclassifiable’
    Artem Oganesyan, Rafael Madero‐Marroquin, Anand Ashwin Patel · 2025 · Current Opinion in Hematology
  48. Immature Platelet Fraction as a Potential Biomarker of Dysregulated Thrombopoiesis in Philadelphia-Negative Myeloproliferative Neoplasms
    Ivan Zekanović, Tina Marketin, Martina Morić Perić, Dražen Zekanović, Ante Vulic, Marija Miloš, Anamarija Bogić, Marta Marcinkovic, Petra Grbić Pavlović, Margareta Radić Antolic et al. · 2026 · Journal of Clinical Medicine
  49. Thrombo-inflammatory endothelial signatures in JAK2 -mutated myeloproliferative neoplasms
    Salma AS Abosabie, Alexandra Boye‐Doe, Mohammed Ali, Nikolai Alexandrovich Podoltsev, David Stegner, Lourdes Mendez, Anish V. Sharda · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  50. Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective
    Omri Y. Cohen, Martin H. Ellis · 2026 · Seminars in Thrombosis and Hemostasis
  51. Superior Mesenteric Artery Thrombosis as a Complication of Polycythemia Vera: A Case Report
    Ljiljana Milić, Dragana Dragan Arbutina, Radosav Radulovic, Marko Šurlan, Aleksandar Karamarković · 2026 · Reports — Medical Cases Images and Videos
  52. Telehealth-Delivered Dietary Counseling in Myeloproliferative Neoplasms: A Randomized Feasibility Study
    Angela G. Fleischman, Jiarui Li, Asmaa Tabban, Shuwei Cai, Andrew Odegaard · 2026 · Nutrients
  53. Thrombose veineuse cérébrale et néoplasies myéloprolifératives : impact physiopathologique de la mutation JAK2V617F
    Marie‐Charlotte Bourrienne · 2023 · theses.fr (ABES)
  54. Genomic profiling for thrombosis risk prediction in myeloproliferative neoplasms
    Simon H Mantha · 2026 · Bleeding Thrombosis and Vascular Biology
  55. Polycythemia Vera in Clinical Practice: A Single-Center Experience Focusing on Thrombotic Complications and Management Strategies
    Çağla Eyüpler Akmercan, Seda Jeral, Fatma Arıkan, Tayfur Toptaş, Işık Atagündüz, Tarık Ercan, Ayşe Tülin Tuğlular, Asu Fergün Yılmaz · 2026 · Indian Journal of Hematology and Blood Transfusion
  56. Long-term outcomes of ropeginterferon alfa-2b-njft in polycythemia vera: a review of safety, efficacy, and potential disease modification
    Ghaith F. Abu-Zeinah, Brandi N. Reeves · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
  57. Chewing the fat: the role of total cholesterol in MPN management
    Andrew Mark Brunner · 2026 · Blood Advances
  58. Coagulation Disorders in Philadelphia Chromosome-negative Myeloproliferative Neoplasms—A Guide for Specialists in Coagulation Disorders
    Christina C. Rolling, Karolin Trautmann‐Grill, Christina Hart, Andreas Tiede · 2026 · Hämostaseologie
  59. Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation
    Aliki Zavoriti, Pierre Miossec · 2026 · ACR Open Rheumatology
  60. Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b
    Veronica Vecchio, Rossella Rosaria Cacciola, Emma Cacciola · 2026 · Life
  61. Atypical Presentation of a Splenic Abscess Secondary to Splenic Artery Thrombosis With Isolated Confusion: A Case Report
    Sarah El Haddad, Paul Boulos, Joe Kadou, Simon Kalisz · 2026 · Cureus
  62. Evaluation of the frequency, risk factors, and outcomes of splanchnic vein thrombosis in myeloproliferative neoplasms: a retrospective cohort study
    Ufuk Demirci, Mehmet Baysal, Elif Aksoy, Metban Güzel Mastanzade, Denis Sabriye Bozer, Duygu Gül, Emine Gültürk, Fazıl Çağrı Hunutlu, Kübra Oral, AYFER GEDÜK et al. · 2026 · Journal of Thrombosis and Thrombolysis
  63. Interferon-α vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark
    Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weis Bjerrum, Mette Brabrand, Sarah Friis Christensen, Christina Schjellerup Eickhardt‐Dalbøge, Christina Ellervik, Daniel El Fassi, Mikael Frederiksen et al. · 2026 · EClinicalMedicine
  64. Managing thrombotic risk in myeloproliferative disorders
    Gerard Gurumurthy, Minji Ho, Jecko V. Thachil, Priya Sriskandarajah · 2026 · Expert Review of Hematology
  65. JAK2V617F Mutation in Ischemic Stroke: Bridging Hematology and Stroke Neurology
    Marie Hvelplund Kristiansen, Lasse Kjær, Vibe Skov, Morten Kranker Larsen, Christina Ellervik, Claus Henrik Nielsen, Hans Carl Hasselbalch, Troels Wienecke · 2026 · Journal of the American Heart Association
  66. Aberrant erythrocyte rigidity in JAK2 V617F myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage
    Aae Suzuki, Liang Zhao, Chelsea L. Thorsheim, Brittany Weiderhold, Changsong Yang, Valerie J. Tutwiler, Carla Casu, Jacob W. Myerson, Elizabeth Olson Hexner, Narla Mohandas et al. · 2026 · Science Translational Medicine